Nov. 18, 2013 - The University of California Center for Accelerated Innovation (UC CAI) invites applications from UC investigators for the development of novel technologies that address heart, lung and blood diseases. UC CAI seeks applicants who propose to advance highly innovative early-stage drugs, devices, and diagnostics toward commercialization.
UC CAI is a collaboration of the five UC medical campuses, including UC San Diego, to accelerate the translation of UC discoveries to benefit patients with heart, lung and blood diseases.
UC CAI anticipates making up to three awards of up to $200K each to support technology development. Awards may be for one or two years. In addition to funding, awardees will receive project-management support and mentoring in entrepreneurship and commercialization. Faculty in all series at all ranks at UC Davis, Irvine, Los Angeles, San Diego and San Francisco are eligible. Postdoctoral scholars are eligible to submit as Co-Principal Investigator (PI) with a faculty PI.
Pre-applications are required and must be submitted by Dec. 20, 2013. Successful applicants will be invited to submit full applications.
To view the RFA, please go to the UC CAI website at uccai.ctsi.ucla.edu and follow the link on the homepage.
A webinar for potential applicants will be held on Nov. 21, 2013 at Noon. The dial-in number can be found at the UC CAI website at uccai.ctsi.ucla.edu. Please follow the link on the homepage.
UC CAI is administered from UCLA and is supported by the National Institute of Heart, Lung and Blood Diseases. It is one of three such centers in the U.S.